RECRUITING

Coenzyme Q10 for Gulf War Illness: A Replication Study

Conditions

Gulf War Syndrome Persian Gulf Syndrome Mitochondrial Disorder, Respiratory Chain

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.

Official Title

Coenzyme Q10 for Gulf War Illness: A Replication Study

Quick Facts

Study Start:2024-09-13

Study Completion:2027-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06515184

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Meets both CDC and Kansas deployment and symptom inclusion criteria. * Does not have a disqualifying condition. * Able to travel to a local Quest facility for study blood draws. * Adequate internet access to allow ZoomPro visit participation and remote survey completion. * Health prior to the Gulf War rated as "very good" or "excellent" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms). * Willing to defer initiation of discretionary treatments or supplements during the expected course of study participation.	* Participating in another clinical trial. * Still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use. * On Coumadin/ warfarin. * Unable to participate for the required duration of the study.

Inclusion Criteria

Exclusion Criteria

* Meets both CDC and Kansas deployment and symptom inclusion criteria.
* Does not have a disqualifying condition.
* Able to travel to a local Quest facility for study blood draws.
* Adequate internet access to allow ZoomPro visit participation and remote survey completion.
* Health prior to the Gulf War rated as "very good" or "excellent" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms).
* Willing to defer initiation of discretionary treatments or supplements during the expected course of study participation.

* Participating in another clinical trial.
* Still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use.
* On Coumadin/ warfarin.
* Unable to participate for the required duration of the study.

Contacts and Locations

Study Contact

Janis B Ritchie, BSN

CONTACT

858-558-4950

jbritchie@ucsd.edu

Principal Investigator

Beatrice A Golomb, MD, PhD

PRINCIPAL_INVESTIGATOR

University of California, San Diego

Study Locations (Sites)

UC San Diego

La Jolla, California, 92093

United States

Collaborators and Investigators

Sponsor: University of California, San Diego

Beatrice A Golomb, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, San Diego

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-13

Study Completion Date2027-12

Study Record Updates

Study Start Date2024-09-13

Study Completion Date2027-12

Terms related to this study

Additional Relevant MeSH Terms

Gulf War Syndrome
Persian Gulf Syndrome
Mitochondrial Disorder, Respiratory Chain